4.6 Article

Targeting Endothelium-Pericyte Cross Talk by Inhibiting VEGF Receptor Signaling Attenuates Kidney Microvascular Rarefaction and Fibrosis

Journal

AMERICAN JOURNAL OF PATHOLOGY
Volume 178, Issue 2, Pages 911-923

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajpath.2010.10.012

Keywords

-

Categories

Funding

  1. National Science Council [97-2314-B-002-049, 99-2628-B-002-013, 96-2314-B-002-059]
  2. National Taiwan University Hospital [98N1264]
  3. Ta-Tung Kidney Foundation
  4. Mrs. Hsiu-Chin Lee Kidney Research Foundation
  5. National Institutes of Health [DK73299, DK84077, DK87389, HL074267-01, NS052830-01]

Ask authors/readers for more resources

Microvascular pericytes and perivascular fibroblasts have recently been identified as the source of scar-producing myofibroblasts that appear after injury of the kidney. We show that cross talk between pericytes and endothelial cells concomitantly dictates development of fibrosis and loss of microvasculature after injury. When either platelet-derived growth factor receptor (R)-beta signaling in pericytes or vascular endothelial growth factor (VEGF)R2 signaling in endothelial cells was blocked by circulating soluble receptor ectodomains, both fibrosis and capillary rarefaction were markedly attenuated during progressive kidney injury. Blockade of either receptor-mediated signaling pathway prevented pericyte differentiation and proliferation, but VEGFR2 blockade also attenuated recruitment of inflammatory macrophages throughout disease progression. Whereas Injury down-regulated angiogenic VEGF164, the dys-angiogenic isomers VEGF120 and VEGF188 were up-regulated, suggesting that pericyte-myofibroblast differentiation triggers endothelial loss by a switch in secretion of VEGF isomers. These findings link fibrogenesis inextricably with microvascular rarefaction for the first time, add new significance to fibrogenesis, and identify novel therapeutic targets. (Am J Pathol 2011, 178:911-923; DOI: 10.1016/j.ajpath.2010.10.012)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available